Unusual Options Activity In Met Life

MetLife, Inc. engages in
the insurance, annuities, employee benefits, and asset management businesses.  The company offers life, dental, group short-
and long-term disability, individual disability, accidental death and
dismemberment, vision, and accident and health coverages, etc. Serving
approximately 100 million customers, MetLife has operations in more than 40
countries and holds leading market positions in the United States, Japan, Latin
America, Asia, Europe and the Middle East.

MetLife was named Life
Insurance Company of the Year at the 2019 Middle East Insurance Industry Awards
(MIIA), organized by Middle East Insurance Review. As the fourth time recipient
of the award, MetLife was commended for its customer focus and recognized for
its efforts in enhancing the customer experience.

Last month, MetLife was
named one of America’s “Most Responsible Companies” by Newsweek
magazine. MetLife was the top-ranked insurance company on Newsweek’s inaugural
list, and number 19 of all 300 companies recognized.

Several months ago, MetLife got into the financial service business when it bought Bequest, Inc. Bequest helps customers draw up legally valid wills and estate planning documents online.

But an interesting move Metlife
made several weeks ago, was when it bought PetFirst Healthcare, a fast-growing
pet health insurance administrator.

The love affair with
pets, in particular cats and dogs goes back to the Egyptian times. Back in the
Egyptian times, dogs and cats were laid to rest in elaborate tombs decorated
with inscriptions, furnished with treasure and scented by incense. It’s
believed that dogs and cats improve human physical and mental health.

68% of households in
America have a pet. This is double the percentage of households that have
children. And pet owners will do practically anything or their cat or dog.

The pet insurance market is under-penetrated and fast-growing. The roughly 85 million families that own pets in the United States spend $18 billionii annually on veterinary care, yet, as of 2018, less than 2 percentiii of pets were insured. Following the acquisition, PetFirst will continue to market pet insurance through animal welfare societies and its direct-to-consumer channel. Beginning in the summer of 2020, MetLife will offer this pet insurance to employers through its leading group benefits distribution channel, reaching approximately 41 million employees and dependents across the U.S.

Katie Blakeley, CEO of PetFirst said, “For more than 15 years, we have proudly focused on developing products and services to meet the growing and evolving needs of pet parents across the U.S. During this time, we have seen pet insurance continue to gain importance as a valuable product for families. With MetLife’s tremendous reach and resources, we see a strong opportunity to help more pet parents get access to pet insurance and alleviate the potential financial burden of a sick or injured pet.”

Source

Metlife now offers a broader suite of products to serve their customers and their financial strengths is admired by investors.  So it only makes sense that yesterday, I noticed unusual options activity. The Smart Money bought over 50,000 March call options with strike price at $55.

What’s interesting about this trade is that price is approaching a weekly demand zone at $54.50. If I had to put my money on the zone or the Smart Money, my money would go to the Smart Money all the time. Stay tuned.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.

Did You Miss The Gold Move…Don’t Worry…

Lat month, gold fell below the psychological whole number of $1500 and was 5% down from the 6-year-peak reached in September due to profit taking and investors wanting to take on more risks. But the charts told you where the sellers were going to step before hand and for that matter where the buyers were going to step in before hand as well based on the monthly supply and demand zones.

Gold never did hit the monthly demand, missed the zone by $5 and has since rallied. The US air strike in Baghdad ordered by President Donald Trump that killed Qassem Soleimani, has been the catalyst not only for gold, but all the other precious metals as well.

But if you missed the rally in gold, don’t worry, according to one article I read this morning, gold is due for a pull back.

Gold is almost guaranteed to record losses in the next two weeks, if history is any guide.

The 14-day Relative Strength Index for the yellow metal soared to 86 on Monday, well above the level of 70 that typically suggests securities are overbought. Previously, there have been only three times since 2000 when the RSI rose above 85, and in each instance bullion fell over the next 10 trading days. The loss averaged 1% compared with a gain of 7% over the previous 10 session.

To be sure, in all three occasions — October 2010, February 2016 and June 2019 — gold eventually resumed its rally. But the momentum had slowed. Gold performs best when interest rates fall and the dollar weakens. Without a further escalation of Middle East tensions, the bulk of the moves in rates and the dollar may be over for now. And the same is probably true for the bounce in gold, at least in the short term.

Source

From my perspective, there is only one reason why gold will pull back and that’s because price are in a monthly supply zone.

Supply and demand zones can often indicate institutional buying and selling. The big market participants cannot just enter one trade at once, they need to slowly build their position over time. And often their positions are so large that they will absorb most unfilled orders before price make big and explosive moves on price charts.

Take for instance the daily supply at $1560. Price entered the daily supply and two days later shot down, but when price returned to the zone several months later, well there weren’t any unfilled orders remaining at that level.

On Sunday, price gapped up into a monthly supply zone and has sense formed a shooting star candle, which is is a bearish and signals a reversal.

But again, the shooting star only formed because the Smart Money was able to fill, unfilled orders at that level. Ideally, what I would like to see is price breach the monthly supply at $1600, pull back, then move higher to the monthly supply at $1700. But this may or may not happen in that order. So if you missed the rally and want to get long, two level to consider are the daily demand at $1520, but I think the better level to go long is at $1475.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.

Colourful

Interesting little flower.



Category#naturephotography
Camera ~ LensNikon D3400 DSLR ~ 40 mm
LocationAustralia

Prompt / Theme: Any fun over Christmas? A wild party or a peaceful holiday?


Giveaway 🎁 – 2 winners
Prize A: 1 Steem Basic Income Unit (default)
Prize B: 100 DEC

Winners will be chosen randomly after post payout. Please specify if you want a particular prize from those listed above.


Rules:
  • 👊 No Upvote, No Resteem, No Follow – just your responding comment required to enter.
  • Comment a reply directly to this post within 7 days. A genuine (family friendly) comment responding to the theme / prompt is required.
  • Posted or Commented 5 or more times during the week this post is active.
  • Not be on @cheetah’s blacklist.

Thanks for having a look 👍

If you liked this photo follow @kiokizz for more.

Worst Stocks Of This Decade

Yesterday, I wrote a post about Facebook. Mark Zuckerberg was onto something in his dorm room at Harvard before he dropped out to focus on Facebook. The company went public in 2012, dropped 50%, switch their focus to mobile and the stock price hasn’t looked back. If one invested $1000 in Facebook during the IPO, you would be up over $5000 or a 500% ROI.

But all that is glitter is not gold. “All that glitters is not gold” is an aphorism stating that not everything that looks precious or true turns out to be so. This can be applied to just about any experience in life. It could also be applied to the stock market.

So the worst stocks of the decade go to:

  1. Apache. Ten-year performance: -78%
  2. Freeport-McMoRan. Ten-year performance: -68%
  3. Devon Energy. Ten-year performance: -66%
  4. The Mosaic Company. Ten-year performance: -65%
  5. CenturyLink. Ten-year performance: -63%
  6. Kraft Heinz. Ten-year performance: -56%
  7. Perrigo. Ten-year performance: -54%
  8. Under Armour. Ten-year performance: -54%
  9. Occidental Petroleum. Ten-year performance: – 51%
  10. Schlumberger. Ten-year performance: -31%

Now if you know these companies, 40% of the companies on the list were in the oil and gas industry. The oil and gas sector (aqua block) was the worst performing sector this year.

Source

  1. Technology: 48%
  2. Communication: 32%
  3. S&P 500: 31%
  4. Financials: 31%
  5. Industrials: 28%
  6. Staples: 27%
  7. Discretionary: 27%
  8. Real Estate: 26%
  9. Materials: 22%
  10. Health Care: 20%
  11. Energy: 10%

And Energy compared to the SPY has under-performed going back for five years.

Now the Dow Dogs involves buying the ten stocks with the highest yields among the thirty in the Dow Jones Industrial Average at the end of each year then holding them until the end of the next year. I don’t know what they call the worst stocks of the decade and potentially hold them for 10 years. But that’s what the Smart Money is doing.

Over the last several weeks, I have been posting about the bullishness going on in the oil and gas industry by way of the Smart Money buying up assets. In particular Sam Zell, Steven Cohen, Ken Griffin and Ray Dalio, all billionaires are buying distressed oil assets in the US.

I have to start looking at this sector as well. Besides that’s the premise of my trading edge, follow the Smart Money. I’m feeling the trade that Ray Dalio bought more of. Ray didn’t become wealthy by buying asset at high prices. Recently Ray’s hedge fund bought an additional 1,177,026 shares to the fund, increasing his stake to over 2.5 million shares.

EQT Corporation operates as a natural gas production company in the United States. It produces natural gas, natural gas liquids (NGLs), and crude oil. EQT is the largest natural gas producer in the U.S. with its asset base located in the heart of the Appalachian Basin with a focus in Pennsylvania, Ohio and West Virginia.

I would like to see price close above $13 as confirmation that price will continue to rise.

I thought EQT Corp was a Master Limited Partnership, but they aren’t, so don’t they pay much dividends. Thus, I’m not interested in own the stock, but look what I just found. The Smart Money already bought LEAP options going out to January of 2021. So best believe I will be buying some options on Monday.

Look at that, went from taking about the worst stocks of the decade to wanting to get in the worst sector of decade on Money.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.

West Coast

Life is sometimes a turmoil.



Category#naturephotography
Camera ~ LensNikon D3400 DSLR ~ 18-55 mm
LocationAustralia

Prompt / Theme: Got your Christmas organised? What’s your favourite present you’ve bought?


Giveaway 🎁 – 2 winners
Prize A: 1 Steem Basic Income Unit (default)
Prize B: 100 DEC

Winners will be chosen randomly after post payout. Please specify if you want a particular prize from those listed above.


Rules:
  • 👊 No Upvote, No Resteem, No Follow – just your responding comment required to enter.
  • Comment a reply directly to this post within 7 days. A genuine (family friendly) comment responding to the theme / prompt is required.
  • Posted or Commented 5 or more times during the week this post is active.
  • Not be on @cheetah’s blacklist.

Thanks for having a look 👍

If you liked this photo follow @kiokizz for more.

So Was The FDA Approval Already Priced Into Amarin’s Stock???

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States.

The company’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels.

About a year ago, Amarin published results from a study that show patients who took Vascepa in addition to a statin experienced a 25% reduction in risk of a heart attack, stroke or other serious cardiac event, compared with patients who took a placebo instead of Vascepa. Thus, Amarin wants to get Vascepa approved for other use, which could potentially generate up $2 billion in sales.

Assuming avg. P/E of 15-24 for companies in the pharmaceutical space and Amarin’s market cap, if Vascepa sales can reach $2 billion in the years to come, the stock would be worth approx $125.

Yesterday, the FDA approved the label extension for Vascepa, but the stock price seem bored by the announcement.

Amarin (AMRN) investors are scratching their heads as to why the stock tumbled following the announcement that the FDA has approved the label extension of the company’s fish oil drug, Vascepa.

That’s good news for Amarin, but less good news for long-term investors. You see, according to the principle of “buy the rumor, sell the news,” the major catalyst for Amarin stock to rise has now been removed, and traders who were awaiting the FDA approval have now reaped all the gains they’re going to get from that particular catalyst. Hence, they’re selling the stock today.

One of these sellers, Stifel’s Derek Archila, wrote in a research note to clients, “We are taking profits post approval and heading to the sidelines.” Indeed, the analyst downgraded AMRN from Buy to Hold, while slightly raising the price target to $28 (from $26), which still implies about 20% upside from current levels.

Source

Many think Amarin’s stock price at $22.88 is a steal and think the stock is worth $50 in the future.    According to FiercePharma, market chatter is now valuing the company at a $20 billion market cap, or $55 a share, if the company is acquired.  So is the stock still worth a buy?

NOTE: since Sept of 2018, the stock has increased from $3 to a little over $20 in 14 months.

To answer the question if the stock is still worth a buy or not, you have to know your time horizon.  Once you know your time horizon, than you can select your target price.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.

Tandem Diabetes Is Worth Keeping An Eye On

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States.

Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Insulin is a hormone that regulates blood sugar. Hyperglycaemia, or raised blood sugar, is a common effect of uncontrolled diabetes and over time leads to serious damage to many of the body’s systems, especially the nerves and blood vessels

More than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report released today by the Centers for Disease Control and Prevention (CDC). The report finds that as of 2015, 30.3 million Americans – 9.4 percent of the U.S. population –have diabetes. Another 84.1 million have prediabetes, a condition that if not treated often leads to type 2 diabetes within five years.

Source

The company’s flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump’s software

Tandem’s t:slim X2 is the smallest durable insulin pump on the market at present and is the only pump in the US market that offers remote software updates. Also, the insulin pump integrates with Dexcom’s G6 continuous glucose monitoring (CGM) system, is the first automated insulin-delivery system approved for use in children as young as six years old.

Tandem Diabetes Care (TNDM) also sells disposable products that are used together with pumps and are replaced every few days.These disposable products are great because they produce reoccurring revenue (think of the disposable razors for the Gillette razor blade…which I hate buying because I know they are overpriced).

Since 2012,Tandem has sold over 72,000 pumps in the US, but 63,000 pumps have been sold in the last four years. In addition, Tandem is also going international to capture opportunities after Johnson & Johnson’s exit from the insulin pump market. This is good because Tandem has penetrated less than 1% of the total addressable diabetes market worldwide.

In recent weeks, Tandem attained Health Canada approval for the t:slim X2 insulin pump with Basal-IQ technology. This approval is expected to accelerate Tandem Diabetes’ global pump shipments and expand its customer base.

But just the other day, Tandem got better news.

Tandem Diabetes (TNDM) nabbed Food and Drug Administration clearance for a new diabetes management system Friday — prodding TNDM stock to pop midday.

The FDA cleared a diabetes management system dubbed Control-IQ to work with Tandem’s insulin pump, dubbed t:slim X2. The closed loop system works with Dexcom’s (DXCM) continuous glucose monitor. The devices automatically adjust insulin to prevent high and low blood sugar.

With the clearance, the FDA also created a new category for interoperable medical devices, known as an automated insulin dosing system. This diabetes management system has the potential to rival devices from Medtronic (MDT).

Source

The potential to take on Medtronic is a big deal as Medtronic is the 800 lb gorilla in the room. One should keep Tandem on their radar screen and the levels to pay attention to are the weekly zones near $80 and near $45.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.

Taiwan Semiconductor…Another Derivative Play On Apple

Taiwan Semiconductor Manufacturing Company Limited (TSM), together with its subsidiaries, engages in manufacturing, selling, packaging, testing, and computer-aided design of integrated circuits and other semiconductor devices. The company manufactures masks and electronic spare parts; researches, develops, designs, manufactures, sells, packages, and tests color filters; and offers customer and engineering support services.

(TSM) is the world’s largest manufacturer of semiconductors.  TSM has been involved with chip design since the 1980s and today produces chips for some of the largest clients in the world. 

One such company is Apple.  TMS produces chips for Apple and gets 20% of its sales from Apple.

Two months ago Apple reportedly boosted component orders for the iPhone 11.  In particular, Apple bumped up orders for the $699 iPhone 11 and the $999 iPhone 11 Pro.  Some analysts are thinking Apple can sell up to 185 million iPhone 11s.   In addition, according to one analyst, Apple AirPods are seeing a surge of demand and could face holiday shortage.

Are you connecting the dots yet?

Apple (AAPL) iPhone chip supplier Taiwan Semiconductor Manufacturing (TSM) saw healthy sales growth in November thanks to strong demand for smartphone processors. Taiwan Semiconductor stock spiked to a record high on the news Thursday.

Taiwan Semi reported revenue of $3.54 billion in November. Sales rose 1.7% from the previous month and popped 9.7% year over year in local currency.

“We think this is largely due to smartphones (seasonal ramp) along with a recovery in data center chips,” RBC Capital Markets analyst Mitch Steves said in a report to clients

Source

The chart suggests to look for a pull back to go long near the $52 level.

Another derivative play on Apple is Qualcomm.  Qualcomm Incorporated designs, develops, manufactures, and markets digital communication products worldwide and the company happens to be right in the center of 5G.

Qualcomm just announced their Snapdragon 865 5G chip which is capable of processing 2 gigapixels per second while delivering speeds of up to 7.5Gbps 5G connectivity.

Apple has plans on selling four new iPhones next year that could all be compatible with ultra-fast 5G wireless networks.

The chart suggests Qualcomm will continue to move higher to at least the $100 level.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.

Can Bill Ackman Do It Again With Agilent???

Trading is nothing but a numbers game…you hope your loses are smaller and hope your winners are much larger than your loses.  Take the billionaire, Bill Ackman of Pershing Square.  The hedge fund’s returns fell 4% in 2017, dropped 13.5% in 2016 and declined 20.5% in 2015, but lets look at some of his recent winners.

A year ago, billionaire, Bill took a $1 billion size position in home improvement Lowe’s because he thought there were opportunities to improve its supply chain to serve customers better and enhance the customer experience through strategic brands and differentiated in-store experiences.  I personally thought Bill was going to take another lost, but boy was I wrong. Bill got in the stock in May of 2018 and thus far that $1 billion is now worth $1.3 billion, a nice paper profit of $300 million thus far.

But Bill’s bigger win was in Chipotle.  Back in 2016, Bill’s Pershing Square bought almost 10% of the shares.  Bill thought Chipotle had a strong brand, differentiated offering, enormous growth opportunity, and was undervalued.

The following year Chipotle hired a new CEO, Brian Niccol.  At Taco Bell, Niccol was known for food menu innovation as well as driving technological advancements to the customer ordering process.  Under Brian’s leadership, digital sales quickly grew as Brian had hoped is that more and more customers will skip other eateries and just order their food at Chipotle.  And then a year later, Brian introduced a loyalty program.

And look what the stock has done since 2016….WOW.

And Chipotle is the gift that keeps on giving as Chipotle made up of 14% of Bill’s hedge fund returns of through mid-2019.

In the most recent news, Bill bought 2.9 million shares in Agilent Technologies on Monday. Agilent provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.  Essentially Agilent is a lab testing equipment maker.

Billionaire investor William Ackman’s hedge fund Pershing Square Capital Management said Monday it bought shares in testing equipment company Agilent Technologies Inc, only its second new investment this year as the fund has reported a 51% return.

Agilent Technologies’ stock price jumped nearly 5% in after-hours trading after Ackman’s investment was made public in a regulatory filing. Ackman’s $7 billion fund earlier in the year bought Berkshire Hathaway Inc shares.

The filing did not say whether the Agilent investment will be active or passive, and Ackman’s spokesman declined to comment. The filing showed that Pershing Square owned 2.9 million shares at the end of September and did not say how big the position is currently. At Monday’s stock price, that stake would be worth $246 million.

Source

The fact that Bill and Warren Buffett own Agilent, something must be up. I really like the monthly demand near $60, but something tells me price isn’t going to get there anytime soon.

But there is also a great level at the weekly demand at $70 to go long as well.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.

Brave and EOS…Going In Opposite Directions

Brave is a decentralized,
open source browser that puts the user first by making online privacy its first
priority.  Brave also claims to be twice
as fast as Chrome on desktop and eight times faster than Safari on mobile.

The man behind the Brave
browser is CEO, Brendan Eich.  Brendan
started his career at Netscape Communications Corporation in April 1995 with
the intent to put Scheme “in the browser.” In early 1998, Brendan co-founded the Mozilla
project. And his most recent initiative was creating the Basic Attention Token (BAT), a cryptocurrency
designed for use in the Brave browser when users view and share in the ad revenue.
In the ecosystem, advertisers will give publishers BATs based on the measured
attention of users. Users will also receive some BATs for participating. They
can donate them back to publishers or use them on the platform

If you don’t care for the
ads, the Brave browser has an inbuilt ad and tracker blocker. The blocker
inhibits trackers from learning more about a user for monetization purposes.
But Brave is trying to fix the internet by improving the ad model.  In the words of founders of Brave “It is a
market filled with middlemen and fraudsters, hurting users, publishers and
advertisers.”  And Brave’s mission of
fixing the internet ad model is gaining traction.

Brave Browser is experiencing robust user growth, gaining another 1.7 million active users over the last three weeks by carving out the privacy niche from Google Chrome.

Since its 1.0 launch mid-November, Brave announced that the open source browser had gained another 1.7 million monthly active users, growing by 19% across all devices. Compared to last year, the numbers are even stronger. The browser’s userbase saw a two-fold increase in monthly active users and tripled its daily active users to 3.3 million.

As of today, verified content creators on the platform increased to over 340,000. The majority of these creators publish to YouTube (229,00), followed by Twitter (37,000), business and personal website publishing (38,000), and Twitch (18,000), among others.

Source

A nice level to potentially go long on the BAT is at the daily demand at $0.14.

The EOS blockchain was developed with the aim of facilitating efficient and scalable decentralized applications (dapps). The blockchain includes an operating-system like set of services and functions that works similarly to the ethereum platform.

Despite EOS being the world’s seventh-largest blockchain by market cap, my first issues is who in the hell has a year long initial coin offering (ICO)…which raised $4.1 billion in crypto for Block.One. My initial thought was they better deliver due to all the hype.

EOS works on an ownership model whereby users own and are entitled to use resources proportional to their stake, rather than having to pay for every transaction. So, in essence, if you hold N tokens of EOS then you are entitled to N*k transactions. And herein lies the issue.

EOS network’s governance issues continue to haunt them as Weiss Ratings recently downgraded the network from B category to C-. Weiss Ratings also posted a Twitter thread explaining why they had to downgrade the project which was once hyped as “Ethereum Killer.”

Weiss Ratings in its tweet claimed that although the public sentiment was right behind the project in its hayday and the platform was known for being a fast, efficient and most important a decentralized ecosystem. However, in the past year, there has been a continuous decline in the decentralization aspect where major whales control the majority of the token flow which could be of a deep concern.

Weiss Ratings claimed that the top 100 EOS token holders who represented a meager 0.01% of the total token holders on the platform, has a whopping 68% of the voting power on the network. This means these whales can easily manipulate the network as per their will.

Source

And now EOS block producers and developers devoted to building decentralized apps (dapps) are making little or no money from contributing to the health of the ecosystem. EOS Tribe even wrote about his experience on Steemit. They cited it’s longer possible to earn funds for maintaining the blockchain without support from major EOS whales.

Thus the chart suggest EOS is headed to the monthly demand at $1.00.

This post is my personal opinion. I’m not a financial advisor, this isn’t financial advise. Do your own research before making investment decisions.